Dietary intake of branched-chain amino acids and pancreatic cancer risk in a case-control study from Italy.
Marta RossiFederica TuratiPanagiota StrikoudiMonica FerraroniMaria ParpinelDiego SerrainoEva NegriCarlo La VecchiaPublished in: The British journal of nutrition (2022)
Circulating branched-chain amino acids (BCAAs), a subgroup of the nine essential amino acids, have been associated to pancreatic cancer risk. The aim of this study is to estimate the relation between BCAA intake from diet and pancreatic cancer risk.We analysed data from a multicentric Italian case-control study, including 326 pancreatic cancer cases and 652 controls, matched to cases by study centre, sex and age. A validated food-frequency questionnaire was used to collect the participants' usual diet before cancer diagnosis (or hospital admission for controls) and to compute dietary intakes of various nutrients, including BCAAs. Odds ratios (ORs) and corresponding confidence intervals (CIs) were computed through logistic regression models conditioned on the matching variables and adjusted for major confounding factors, including total energy intake.We found a positive association between the BCAA intake and pancreatic cancer risk (OR for the third quartile=1.88, 95% CI=1.08-3.26; OR for the fourth quartile =2.17, 95% CI=1.17-4.06), with a significant trend in risk. The association persisted after excluding subjects with diabetes and family history of pancreatic cancer, and across strata of selected covariates.These data support and quantify the association between dietary BCAAs and pancreatic cancer, previously suggested by studies on circulating BCAAs.
Keyphrases
- amino acid
- physical activity
- emergency department
- electronic health record
- healthcare
- cardiovascular disease
- weight loss
- weight gain
- magnetic resonance
- machine learning
- magnetic resonance imaging
- adipose tissue
- young adults
- papillary thyroid
- body mass index
- skeletal muscle
- squamous cell
- artificial intelligence
- adverse drug
- contrast enhanced
- phase iii